Does Rallies show 13F holders for CCCC?

Yes. Rallies tracks hedge fund and 13F ownership data for CCCC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CCCC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CCCC. It does not provide personalized investment advice.

CCCC (C4 Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

C4 Therapeutics, Inc. (CCCC) is a publicly traded Healthcare sector company. As of May 21, 2026, CCCC trades at $3.34 with a market cap of $356.03M and a P/E ratio of -2.56. CCCC moved +5.31% today. Year to date, CCCC is +61.58%; over the trailing twelve months it is +121.62%. Its 52-week range spans $1.09 to $7.14. Analyst consensus is strong buy with an average price target of $13.60. Rallies surfaces CCCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CCCC stock?

Hedge funds tracked by Rallies that own CCCC include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for C4 Therapeutics, Inc..

CCCC Key Metrics

Key financial metrics for CCCC
Metric	Value
Price	$3.34
Market Cap	$356.03M
P/E Ratio	-2.56
EPS	$-1.27
Dividend Yield	0.00%
52-Week High	$7.14
52-Week Low	$1.09
Volume	5.24K
Avg Volume	0
Revenue (TTM)	$35.95M
Net Income	$-104.99M
Gross Margin	0.00%

Top Hedge Funds Holding CCCC

Orbimed Advisors holds 856.35K shares of CCCC, changed -39.05% as of Mar 31, 2026.
Panagora Asset holds 86.76K shares of CCCC, changed +0.00% as of Mar 31, 2026.
Farallon Capital holds 28.00K shares of CCCC, changed +0.00% as of Mar 31, 2026.

Latest CCCC News

C4 Therapeutics Launches Cemsidomide Trials, Reports $268.3M Cash Runway — May 12, 2026
C4 Therapeutics Launches Phase 1b Cemsidomide and Elranatamab Trial in RRMM — Mar 25, 2026
C4 Therapeutics’ Price Target Raised to $30 as Phase 2 Trial Doses First Patient and Issues 85,480 Options — Mar 10, 2026
C4 Therapeutics Doses First Patient in Phase 2 MOMENTUM Trial of Cemsidomide — Mar 5, 2026
C4 Therapeutics Q4 Revenue Rises to $11M, Cash Runway Extended to 2028 — Feb 26, 2026

Recent CCCC Insider Trades

REYNO LEONARD sold 10.00K (~$22.20K) on Jan 16, 2026.
Boyle Scott N sold 669 (~$2.11K) on Feb 18, 2025.
Boyle Scott N sold 490 (~$1.54K) on Feb 14, 2025.

CCCC Analyst Consensus

6 analysts cover CCCC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.60.

Common questions about CCCC

Who owns CCCC stock?: Hedge funds tracked by Rallies that own CCCC include Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for C4 Therapeutics, Inc..
Does Rallies show 13F holders for CCCC?: Yes. Rallies tracks hedge fund and 13F ownership data for CCCC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CCCC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CCCC. It does not provide personalized investment advice.